Degludec's Japanese launch delayed as Novo holds out on pricing
This article was originally published in Scrip
Japan may have been the first country worldwide to grant a regulatory approval to Novo Nordisk's insulin degludec product Tresiba, but the once-daily basal insulin analog will not now be launched in the country until next year, possibly after it reaches its first European markets.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.